Literature DB >> 22608401

Multimodality therapy offers a chance for cure in patients with pancreatic adenocarcinoma deemed unresectable at first operative exploration.

Mark J Truty1, Ryan M Thomas, Matthew H Katz, Jean-Nicolas Vauthey, Christopher Crane, Gaury R Varadhachary, Robert A Wolff, James L Abbruzzese, Jeffrey E Lee, Jason B Fleming.   

Abstract

BACKGROUND: Patients identified at surgical exploration with unresectable pancreatic ductal adenocarcinoma receive palliative, noncurative therapy. We hypothesized that accurate radiographic restaging, multimodality treatment, and advanced surgical technique can offer patients deemed unresectable at previous exploration the possibility for curative salvage pancreatectomy. STUDY
DESIGN: Review of a prospectively maintained pancreatic ductal adenocarcinoma database identified all patients (1990 to 2010) evaluated after being deemed unresectable at first exploration elsewhere. Referring hospitals were categorized per National Cancer Data Base criteria as academic, community, or international. Patients were restaged using objective imaging (CT) criteria and classified based on anatomic resectability. Clinicopathologic factors and cancer-related outcomes were assessed.
RESULTS: We evaluated 88 patients who underwent previously unsuccessful resection attempts at academic (n = 50), community (n = 25), and international (n = 13) centers. Radiographic restaging confirmed that 7 (8%) patient tumors were locally advanced and unresectable, but 81 (92%) were resectable (n = 61) or borderline resectable (n = 20). Using a surgery first (9%) or preoperative chemoradiation (91%) approach, successful reoperative pancreatectomy was performed in 66 (81%) patients, with 94% receiving R0 resections. Vascular resection/reconstruction was required in 30 (46%) patients and 50 (76%) required complex revision of previously created biliary/gastrointestinal bypass. The major complication rate was 20% and 3 (4.5%) patients died perioperatively. Median overall survival was 29.6 months for successfully resected patients vs 10.6 and 5.1 months (p < 0.0001) for those patients with locally advanced unresectable disease at initial referral or in whom metastatic disease developed before resection, respectively.
CONCLUSIONS: In this very selected cohort of high-risk patients, the majority had anatomically resectable tumors on restaging. Accurate radiographic restaging, a multimodality treatment strategy, and advanced surgical techniques can provide an opportunity for cure in a substantial proportion of select patients who were deemed unresectable at exploration.
Copyright © 2012 American College of Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22608401      PMCID: PMC4086164          DOI: 10.1016/j.jamcollsurg.2012.03.024

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  27 in total

1.  The National Cancer Data Base: a clinical surveillance and quality improvement tool.

Authors:  David P Winchester; Andrew K Stewart; Connie Bura; R Scott Jones
Journal:  J Surg Oncol       Date:  2004-01       Impact factor: 3.454

2.  Reoperative pancreaticoduodenectomy.

Authors:  H Hashimi
Journal:  Ann Surg       Date:  1995-01       Impact factor: 12.969

3.  Reoperative completion pancreatectomy for suspected malignant disease of the pancreas.

Authors:  Harish Lavu; Leonard J Nowcid; Matthew J Klinge; Krishnaraj Mahendraraj; Dane R Grenda; Patricia K Sauter; Ernest L Rosato; Eugene P Kennedy; Charles J Yeo
Journal:  J Surg Res       Date:  2011-05-19       Impact factor: 2.192

4.  Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome.

Authors:  Peter W T Pisters; Robert A Wolff; Nora A Janjan; Karen R Cleary; Chusilp Charnsangavej; Christopher N Crane; Renato Lenzi; J Nicolas Vauthey; Jeffrey E Lee; James L Abbruzzese; Douglas B Evans
Journal:  J Clin Oncol       Date:  2002-05-15       Impact factor: 44.544

5.  Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas.

Authors:  D B Evans; T A Rich; D R Byrd; K R Cleary; J H Connelly; B Levin; C Charnsangavej; C J Fenoglio; F C Ames
Journal:  Arch Surg       Date:  1992-11

Review 6.  Preoperative chemoradiation in resectable pancreatic cancer.

Authors:  Nicole M Chandler; Jonathan J Canete; Keith E Stuart; Mark P Callery
Journal:  J Hepatobiliary Pancreat Surg       Date:  2003

7.  Benefit of venous resection for ductal adenocarcinoma of the pancreatic head.

Authors:  Mark Hartel; Marco Niedergethmann; Michael Farag-Soliman; Jörg W Sturm; Axel Richter; Michael Trede; Stefan Post
Journal:  Eur J Surg       Date:  2002

8.  Thin-section contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms.

Authors:  G M Fuhrman; C Charnsangavej; J L Abbruzzese; K R Cleary; R G Martin; C J Fenoglio; D B Evans
Journal:  Am J Surg       Date:  1994-01       Impact factor: 2.565

Review 9.  Reoperative pancreaticoduodenectomy.

Authors:  D S Tyler; D B Evans
Journal:  Ann Surg       Date:  1994-02       Impact factor: 12.969

10.  Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey.

Authors:  Daniel Dindo; Nicolas Demartines; Pierre-Alain Clavien
Journal:  Ann Surg       Date:  2004-08       Impact factor: 12.969

View more
  12 in total

1.  Computed tomography-based diagnostics might be insufficient in the determination of pancreatic cancer unresectability.

Authors:  Vyacheslav I Egorov; Roman V Petrov; Elena N Solodinina; Gregory G Karmazanovsky; Natalia S Starostina; Natalia A Kuruschkina
Journal:  World J Gastrointest Surg       Date:  2013-04-27

2.  Optimal indication of neoadjuvant chemoradiotherapy for pancreatic cancer.

Authors:  Masayuki Sho; Takahiro Akahori; Toshihiro Tanaka; Shoichi Kinoshita; Minako Nagai; Satoshi Nishiwada; Tetsuro Tamamoto; Hideyuki Nishiofuku; Chiho Ohbayashi; Masatoshi Hasegawa; Kimihiko Kichikawa; Yoshiyuki Nakajima
Journal:  Langenbecks Arch Surg       Date:  2015-05-01       Impact factor: 3.445

3.  Neoadjuvant Therapy in Clinical Stage II Pancreatic Adenocarcinoma.

Authors:  Alexandra Snyder; Peter Allen; Ali Shamseddine; Ali Haydar; Mohamed Eloubeidi; Walid Faraj; Mohamed Khalife; Sally Temraz; Ashwaq El-Olayan; David P Kelsen; Fadi El-Merhi; Mohamed Naghy; Leonard B Saltz; Ghassan K Abou-Alfa; Eileen M O'Reilly
Journal:  Gastrointest Cancer Res       Date:  2012-09

4.  Overuse of surgery in patients with pancreatic cancer. A nationwide analysis in Italy.

Authors:  Gianpaolo Balzano; Giovanni Capretti; Giuditta Callea; Elena Cantù; Flavia Carle; Raffaele Pezzilli
Journal:  HPB (Oxford)       Date:  2016-02-05       Impact factor: 3.647

5.  Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer.

Authors:  Brian A Boone; Jennifer Steve; Alyssa M Krasinskas; Amer H Zureikat; Barry C Lembersky; Michael K Gibson; Ronald G Stoller; Herbert J Zeh; Nathan Bahary
Journal:  J Surg Oncol       Date:  2013-09       Impact factor: 3.454

6.  Importance of b value in diffusion weighted imaging for the diagnosis of pancreatic cancer.

Authors:  Jin-Gang Hao; Jia-Ping Wang; Ya-Lv Gu; Ming-Liang Lu
Journal:  World J Gastroenterol       Date:  2013-10-21       Impact factor: 5.742

7.  Neoadjuvant therapy prior to surgical resection for previously explored pancreatic cancer patients is associated with improved survival.

Authors:  Fengchun Lu; Kevin C Soares; Jin He; Ammar A Javed; John L Cameron; Neda Rezaee; Timothy M Pawlik; Christopher L Wolfgang; Matthew J Weiss
Journal:  Hepatobiliary Surg Nutr       Date:  2017-06       Impact factor: 7.293

8.  Phase II Trial of Cetuximab and Conformal Radiotherapy Only in Locally Advanced Pancreatic Cancer with Concurrent Tissue Sampling Feasibility Study.

Authors:  Agata I Rembielak; Pooja Jain; Andrew S Jackson; Melanie M Green; Gillian R Santorelli; Gillian A Whitfield; Adrian Crellin; Angel Garcia-Alonso; Ganesh Radhakrishna; James Cullen; M Ben Taylor; Ric Swindell; Catharine M West; Juan Valle; Azeem Saleem; Patricia M Price
Journal:  Transl Oncol       Date:  2014-02-01       Impact factor: 4.243

9.  Health Insurance Expansion and Treatment of Pancreatic Cancer: Does Increased Access Lead to Improved Care?

Authors:  Andrew P Loehrer; David C Chang; Matthew M Hutter; Zirui Song; Keith D Lillemoe; Andrew L Warshaw; Cristina R Ferrone
Journal:  J Am Coll Surg       Date:  2015-10-09       Impact factor: 6.113

10.  Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma.

Authors:  Marine Gilabert; Brice Chanez; Young Soo Rho; Marc Giovanini; Olivier Turrini; Gerald Batist; Petr Kavan; Jean Luc Raoul
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.